The wrath of the pandemic swept through our nation and continues to run rampant, testing our resiliency as nurses. Nurse leaders, we must continue to lead by example and remain a united front with our team.
Nurses continue to be ranked as the most trusted professionals and the COVID-19 pandemic has further validated the reason why. 1 Despite this fact, there is no denying that a severe workforce shortage in nursing continues to rise due to a combination of factors, many nurses are nearing retirement, fewer individuals are entering the nursing workforce, and nurses are leaving the profession due to burnout and unsatisfying work conditions. 2
As a nurse leader, you must maintain your resiliency and lead authentically. Authentic leadership describes a pattern of behavior in a leader that is characterized by efforts to help employees find meaning in their work; build optimism and commitment; encourage transparency and develop trusting relationships; and promote an inclusive and positive work environment.3
The wrath of the pandemic swept through our nation and continues to run rampant, testing our resiliency as nurses. Nurse leaders, we must continue to lead by example and remain a united front with our team.
Following are strategies that authentic nurse leaders should employ with their staff working during a pandemic:
Nurse leaders, these strategies are not meant to be inclusive; they are intended to provide you with resources to support your staff during stressful and difficult times. Develop strategies to empower nurses, create a positive work environment that fosters communication, and support your nursing team to maintain and improve work satisfaction.
References:
Maggie A. Smith is a director-at-large for the national Oncology Nursing Society (ONS), as well as nominating-chair and immediate-past president of the Chicago Chapter of ONS. Her clinical and research interest include being a voice for underrepresented and underserved populations. She is also, involved in community outreach and breast health education.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.